<p>德克萨斯州教师退休系统在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Bio-Techne Corp（NASDAQ:TECH - 免费报告）的股份增加了 52.5%。该公司在季度内购买了 12,187 股后，持有 35,414 股生物技术公司的股票。截至最近的 SEC 文件，德克萨斯州教师退休系统在 Bio-Techne 的持股价值为 1,822,000 美元。</p>
<ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近买入点</li>
</ul>
<p>其他一些大型投资者最近也买卖了 TECH 的股票。Nisa Investment Advisors LLC 在第二季度将其在 Bio-Techne 的股份增加了 8.4%。Nisa Investment Advisors LLC 目前持有 67,958 股生物技术公司的股票，价值 3,496,000 美元，此前在上个季度购买了 5,250 股。新泽西州共同养老金基金 D 在第二季度将其在 Bio-Techne 的股份增加了 1.6%。新泽西州共同养老金基金 D 目前持有 52,511 股生物技术公司的股票，价值 2,702,000 美元，此前在此期间购买了 844 股。Sage Mountain Advisors LLC 在第二季度购买了 Bio-Techne 的新股份，价值 230,000 美元。AlphaQuest LLC 在第二季度将其在 Bio-Techne 的持股增加了 392.5%。AlphaQuest LLC 目前持有 2,822 股生物技术公司的股票，价值 145,000 美元，此前在此期间购买了 2,249 股。最后，住友三井信托集团在第二季度将其在 Bio-Techne 的股份增加了 15.7%。住友三井信托集团目前持有 2,349,712 股生物技术公司的股票，价值 120,893,000 美元，此前在上个季度购买了 319,177 股。机构投资者和对冲基金持有该公司 98.95% 的股票。</p>
<h2>Bio-Techne 股票下跌 2.1%</h2>
<p>NASDAQ TECH 的股票周二开盘价为 61.26 美元。Bio-Techne Corp 的 52 周低点为 46.01 美元，52 周高点为 80.80 美元。该公司的 50 日移动平均线为 57.34 美元，200 日移动平均线为 53.53 美元。该股票的市值为 95.4 亿美元，市盈率为 133.18，市盈增长比率为 3.63，贝塔值为 1.48。该公司的速动比率为 2.38，流动比率为 3.46，债务与股本比率为 0.18。</p>
<p>Bio-Techne（NASDAQ:TECH - 获取免费报告）最近在 8 月 6 日（星期三）公布了季度财报。该生物技术公司报告季度每股收益（EPS）为 0.53 美元，超出市场共识预期的 0.50 美元，超出 0.03 美元。Bio-Techne 的净利润率为 6.02%，股本回报率为 13.43%。该公司在本季度的收入为 3.1696 亿美元，而分析师预期为 3.1514 亿美元。在去年同期，该公司每股收益为 0.49 美元。与去年同期相比，该公司的季度收入增长了 3.6%。分析师预计 Bio-Techne Corp 在当前年度将发布 1.67 美元的每股收益。</p>
<h2>Bio-Techne 股息公告</h2>
<p>该公司最近还披露了季度股息，已于 8 月 29 日（星期五）支付。8 月 18 日（星期一）登记的股东获得了 0.08 美元的股息。除息日期为 8 月 18 日（星期一）。这相当于每年 0.32 美元的股息，收益率为 0.5%。Bio-Techne 的派息比率目前为 69.57%。</p>
<h2>分析师评级上调和下调</h2>
<p>一些研究公司最近对 TECH 发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Bio-Techne 股票的 “卖出（d+）” 评级。加拿大丰业银行将 Bio-Techne 的目标价从 90.00 美元下调至 75.00 美元，并在 7 月 11 日（星期五）的报告中对该股票给予 “行业表现优于大盘” 的评级。Zacks Research 在 10 月 6 日（星期一）的报告中将 Bio-Techne 的评级从 “强烈卖出” 上调至 “持有”。Stephens 在 7 月 22 日（星期二）的研究报告中将 Bio-Techne 的评级上调至 “强烈买入”，并设定了 65.00 美元的目标价。最后，Cowen 在 10 月 14 日（星期二）的研究报告中重申了对 Bio-Techne 股票的 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 70.58 美元。</p>
<p><strong>阅读我们关于 TECH 的最新股票报告</strong></p>
<h2>关于 Bio-Techne</h2>
<p>（免费报告）</p>
<p>Bio-Techne 公司及其子公司在美国、英国、欧洲其他地区、中东和非洲、大中华区、亚太其他地区及国际市场开发、制造和销售生命科学试剂、仪器和服务，服务于研究和临床诊断市场。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Bio-Techne</li>
<li>股息之王宝洁在财报后下跌时值得买入</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会随着人工智能和电动车的增长而翻倍</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>感恩节最佳本地肉铺 [2025 年调查]</li>
<li>股票行业对成功投资的重要性</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
<p>在你考虑 Bio-Techne 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bio-Techne 并不在名单上。</p>
<p>虽然 Bio-Techne 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TECH

<p>德克萨斯州教师退休系统在第二季度将其在 Bio-Techne Corp（纳斯达克代码：TECH）的持股增加了 52.5%，目前持有 35,414 股，价值 182 万美元。其他投资者也提高了他们的持仓。Bio-Techne 的股票下跌了 2.1%，市值为 95.4 亿美元，市盈率为 133.18。该公司报告第二季度每股收益为 0.53 美元，超出预期，并宣布季度股息为 0.08 美元。分析师的评级不一，平均目标价为 70.58 美元</p>

<p>Teacher Retirement System of Texas grew its stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) by 52.5% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm owned 35,414 shares of the biotechnology company's stock after buying an additional 12,187 shares during the quarter. Teacher Retirement System of Texas' holdings in Bio-Techne were worth $1,822,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>德克萨斯州教师退休系统在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Bio-Techne Corp（NASDAQ:TECH - 免费报告）的股份增加了 52.5%。该公司在季度内购买了 12,187 股后，持有 35,414 股生物技术公司的股票。截至最近的 SEC 文件，德克萨斯州教师退休系统在 Bio-Techne 的持股价值为 1,822,000 美元。</p>
</div><ul>
<li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li>
</ul>
<div class="lb-trans"><ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近买入点</li>
</ul>
</div><p>A number of other large investors also recently bought and sold shares of TECH. Nisa Investment Advisors LLC grew its position in shares of Bio-Techne by 8.4% in the second quarter. Nisa Investment Advisors LLC now owns 67,958 shares of the biotechnology company's stock valued at $3,496,000 after purchasing an additional 5,250 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Bio-Techne by 1.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 52,511 shares of the biotechnology company's stock worth $2,702,000 after buying an additional 844 shares during the period. Sage Mountain Advisors LLC purchased a new position in Bio-Techne in the second quarter valued at $230,000. AlphaQuest LLC boosted its holdings in Bio-Techne by 392.5% in the second quarter. AlphaQuest LLC now owns 2,822 shares of the biotechnology company's stock valued at $145,000 after purchasing an additional 2,249 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in Bio-Techne by 15.7% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,349,712 shares of the biotechnology company's stock valued at $120,893,000 after buying an additional 319,177 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也买卖了 TECH 的股票。Nisa Investment Advisors LLC 在第二季度将其在 Bio-Techne 的股份增加了 8.4%。Nisa Investment Advisors LLC 目前持有 67,958 股生物技术公司的股票，价值 3,496,000 美元，此前在上个季度购买了 5,250 股。新泽西州共同养老金基金 D 在第二季度将其在 Bio-Techne 的股份增加了 1.6%。新泽西州共同养老金基金 D 目前持有 52,511 股生物技术公司的股票，价值 2,702,000 美元，此前在此期间购买了 844 股。Sage Mountain Advisors LLC 在第二季度购买了 Bio-Techne 的新股份，价值 230,000 美元。AlphaQuest LLC 在第二季度将其在 Bio-Techne 的持股增加了 392.5%。AlphaQuest LLC 目前持有 2,822 股生物技术公司的股票，价值 145,000 美元，此前在此期间购买了 2,249 股。最后，住友三井信托集团在第二季度将其在 Bio-Techne 的股份增加了 15.7%。住友三井信托集团目前持有 2,349,712 股生物技术公司的股票，价值 120,893,000 美元，此前在上个季度购买了 319,177 股。机构投资者和对冲基金持有该公司 98.95% 的股票。</p>
</div><h2>Bio-Techne Stock Down 2.1%</h2>
<div class="lb-trans"><h2>Bio-Techne 股票下跌 2.1%</h2>
</div><p>Shares of NASDAQ TECH opened at $61.26 on Tuesday. Bio-Techne Corp has a 52-week low of $46.01 and a 52-week high of $80.80. The firm has a fifty day moving average of $57.34 and a 200-day moving average of $53.53. The stock has a market capitalization of $9.54 billion, a PE ratio of 133.18, a P/E/G ratio of 3.63 and a beta of 1.48. The company has a quick ratio of 2.38, a current ratio of 3.46 and a debt-to-equity ratio of 0.18.</p>
<div class="lb-trans"><p>NASDAQ TECH 的股票周二开盘价为 61.26 美元。Bio-Techne Corp 的 52 周低点为 46.01 美元，52 周高点为 80.80 美元。该公司的 50 日移动平均线为 57.34 美元，200 日移动平均线为 53.53 美元。该股票的市值为 95.4 亿美元，市盈率为 133.18，市盈增长比率为 3.63，贝塔值为 1.48。该公司的速动比率为 2.38，流动比率为 3.46，债务与股本比率为 0.18。</p>
</div><p>Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The company had revenue of $316.96 million during the quarter, compared to analysts' expectations of $315.14 million. During the same period in the previous year, the company earned $0.49 EPS. The business's quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts anticipate that Bio-Techne Corp will post 1.67 EPS for the current year.</p>
<div class="lb-trans"><p>Bio-Techne（NASDAQ:TECH - 获取免费报告）最近在 8 月 6 日（星期三）公布了季度财报。该生物技术公司报告季度每股收益（EPS）为 0.53 美元，超出市场共识预期的 0.50 美元，超出 0.03 美元。Bio-Techne 的净利润率为 6.02%，股本回报率为 13.43%。该公司在本季度的收入为 3.1696 亿美元，而分析师预期为 3.1514 亿美元。在去年同期，该公司每股收益为 0.49 美元。与去年同期相比，该公司的季度收入增长了 3.6%。分析师预计 Bio-Techne Corp 在当前年度将发布 1.67 美元的每股收益。</p>
</div><h2>Bio-Techne Dividend Announcement</h2>
<div class="lb-trans"><h2>Bio-Techne 股息公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 18th were issued a $0.08 dividend. The ex-dividend date was Monday, August 18th. This represents a $0.32 dividend on an annualized basis and a yield of 0.5%. Bio-Techne's payout ratio is currently 69.57%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，已于 8 月 29 日（星期五）支付。8 月 18 日（星期一）登记的股东获得了 0.08 美元的股息。除息日期为 8 月 18 日（星期一）。这相当于每年 0.32 美元的股息，收益率为 0.5%。Bio-Techne 的派息比率目前为 69.57%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>A number of research firms have recently commented on TECH. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Bio-Techne in a report on Wednesday, October 8th. Scotiabank lowered their price objective on Bio-Techne from $90.00 to $75.00 and set a &#34;sector outperform&#34; rating on the stock in a report on Friday, July 11th. Zacks Research raised Bio-Techne from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Stephens raised Bio-Techne to a &#34;strong-buy&#34; rating and set a $65.00 price target on the stock in a research note on Tuesday, July 22nd. Finally, Cowen restated a &#34;buy&#34; rating on shares of Bio-Techne in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $70.58.</p>
<div class="lb-trans"><p>一些研究公司最近对 TECH 发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Bio-Techne 股票的 “卖出（d+）” 评级。加拿大丰业银行将 Bio-Techne 的目标价从 90.00 美元下调至 75.00 美元，并在 7 月 11 日（星期五）的报告中对该股票给予 “行业表现优于大盘” 的评级。Zacks Research 在 10 月 6 日（星期一）的报告中将 Bio-Techne 的评级从 “强烈卖出” 上调至 “持有”。Stephens 在 7 月 22 日（星期二）的研究报告中将 Bio-Techne 的评级上调至 “强烈买入”，并设定了 65.00 美元的目标价。最后，Cowen 在 10 月 14 日（星期二）的研究报告中重申了对 Bio-Techne 股票的 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 70.58 美元。</p>
</div><p><strong>Read Our Latest Stock Report on TECH</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TECH 的最新股票报告</strong></p>
</div><h2>About Bio-Techne</h2>
<div class="lb-trans"><h2>关于 Bio-Techne</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.</p>
<div class="lb-trans"><p>Bio-Techne 公司及其子公司在美国、英国、欧洲其他地区、中东和非洲、大中华区、亚太其他地区及国际市场开发、制造和销售生命科学试剂、仪器和服务，服务于研究和临床诊断市场。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Bio-Techne</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>The Best Local Butchers for Thanksgiving [2025 Survey]</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Bio-Techne</li>
<li>股息之王宝洁在财报后下跌时值得买入</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会随着人工智能和电动车的增长而翻倍</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>感恩节最佳本地肉铺 [2025 年调查]</li>
<li>股票行业对成功投资的重要性</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TECH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
</div><p>Before you consider Bio-Techne, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bio-Techne 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bio-Techne 并不在名单上。</p>
</div><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bio-Techne 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bio-Techne Corp $TECH 的股份被德克萨斯州教师退休系统收购